entecavir and Aortitis

entecavir has been researched along with Aortitis* in 1 studies

Other Studies

1 other study(ies) available for entecavir and Aortitis

Article	Year
[Aortoarteritis in HBV-associated liver cirrhosis: diagnostics, therapeutic strategy, and prognosis]. Klinicheskaia meditsina, 2013, Volume: 91, Issue:6 A case of decompensated liver cirrhosis in a women with a long silent period of HBV infection is presented. The first manifestation was generalized vasculitis involving small and medium-size vessels and elastic-type arteries with the development of aortoarteritis. Proper interpretation of manifestations of viral liver cirrhosis allowed for immunosuppressive treatment in combination with effective antiviral drugs. As a result, aviremia, regression of vasculitis and portal hypertension along with considerable improvement of the prognosis were achieved. Topics: Antiviral Agents; Aortitis; Arteritis; Dose-Response Relationship, Drug; Female; Glucocorticoids; Guanine; Hepatitis B, Chronic; Humans; Immunosuppressive Agents; Liver Cirrhosis; Middle Aged; Monitoring, Immunologic; Positron-Emission Tomography; Treatment Outcome	2013

Article

Year

[Aortoarteritis in HBV-associated liver cirrhosis: diagnostics, therapeutic strategy, and prognosis].

Klinicheskaia meditsina, 2013, Volume: 91, Issue:6

A case of decompensated liver cirrhosis in a women with a long silent period of HBV infection is presented. The first manifestation was generalized vasculitis involving small and medium-size vessels and elastic-type arteries with the development of aortoarteritis. Proper interpretation of manifestations of viral liver cirrhosis allowed for immunosuppressive treatment in combination with effective antiviral drugs. As a result, aviremia, regression of vasculitis and portal hypertension along with considerable improvement of the prognosis were achieved.

Topics: Antiviral Agents; Aortitis; Arteritis; Dose-Response Relationship, Drug; Female; Glucocorticoids; Guanine; Hepatitis B, Chronic; Humans; Immunosuppressive Agents; Liver Cirrhosis; Middle Aged; Monitoring, Immunologic; Positron-Emission Tomography; Treatment Outcome

2013